Validation and Advanced Development of Emerging Technologies for Cancer Research (R33)

Post Date

October 26th 2009

Application Due Date

September 30th 2010

Funding Opportunity Number

RFA-CA-10-004

CFDA Number(s)

93.393
93.394
93.395
93.396

Funding Instrument Type(s)

Grant

Funding Activity Categories

Education
Health

Eligibility Categories

State Governments
Public and State Controlled Institutions of Higher Education
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $2250000

• Award Range:

  $None - $300000

Grant Description

Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing research projects on the advanced development of emerging molecular and cellular analysis technologies through technical/analytical validation in an appropriate cancer-relevant biological system. An emerging technology is defined as one that has passed the pilot developmental stage and shows promise, but has not yet been evaluated within the context of its intended use. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits R33 applications; this mechanism is suitable for projects where proof-of-principle of the proposed technology or methodology has been established and supportive preliminary data are available. Projects proposed to this FOA should reflect the potential to produce a major impact in a broad area of cancer-relevant research. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation and will be returned as non-responsive. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Mechanism of Support. This FOA will utilize the R33 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-CA-10-003, that solicits applications under the NIH Exploratory/Developmental R21 grant mechanism. Funds Available and Anticipated Number of Awards. The NCI intends to commit a total of approximately $2,250,000 to this FOA in fiscal year 2010 to award up to 7 grants.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-10-004.html